The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1163
ISSUE1163
August 19, 2003
Omalizumab (Xolair): An Anti-IgE Antibody For Asthma
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Omalizumab (Xolair): An Anti-IgE Antibody For Asthma
August 19, 2003 (Issue: 1163)
The FDA has approved release of omalizumab (oh mah lye zoo mab; Xolair - Genentech, Novartis), a humanized monoclonal antibody given subcutaneously that binds to immunoglobulin E (IgE). The drug is labeled for patients at least 12 years old with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.